Transactivator From the X-gene Region (Tax)

Alfa Cytology provides efficient solutions for targeting tax drug development services through in-depth investigation of the human T-cell leukemia virus type 1 (HTLV-1) Tax protein, we explore its critical role in viral gene expression. Using advanced experimental techniques and bioinformatics analysis, we validate Tax as a viable drug target.

Oncogenic Functions of HTLV-1 Tax

Tax plays a pivotal role in controlling the expression of viral genes and enlists host transcription factors like cyclic AMP response element-binding protein along with coactivators, such as CREB binding protein and p300, to the long terminal repeat for stimulating the viral promoter. Studies have demonstrated that HTLV-1 Tax exerts a pro-survival function in T cells affected by the virus through augmenting the levels of antiapoptotic proteins from the Bcl-2 family.

Fig. 1. The immunodominant protein Tax will be presented via MHCI on latently infected cells. (Schnell, A.P. et al., 2021)

The HTLV-1 transactivator protein, Tax, has been identified as a protein of significant interest in HTLV-1 pathogenesis as it is a potent activator of a variety of transcription pathways and is sufficient to immortalize T-cells in vitro and thus plays an important role in cellular transformation. Alfa Cytology provides comprehensive HTLV-1 Tax-related development services, including but not limited to the following.

Development of Latency Reversing Agents

Our services focus on the development of novel therapeutic strategies aimed at transiently inducing viral gene expression and antigen presentation of Tax. This disruption of equilibrium is advantageous for enhancing the CTL response against HTLV-1.

Development of Histone Deacetylase Inhibitors

Our Histone Deacetylase Inhibitors (HDACi) development services are built upon an established pharmacophore model. The overall framework comprises a cap, which binds to the HDAC surface, facilitating ligand-receptor interactions. A hydrophobic linker region connects the cap to a zinc-binding group (ZBG), serving as the functional moiety of the HDACi. We offer development services for various categories of HDACi.

Development of P-TEFb-modulating Agents

Positive transcription elongation factor (P-TEFb) activity is regulated through its interaction with various proteins. We provide development services for agents that target both high molecular weight (HMW) and low molecular weight (LMW) complexes. The agents developed by our team can specifically target these complexes to facilitate the release of P-TEFb, promoting its binding with the Tax.

Development of Immunotherapy

As a trusted provider of HTLV-1 drug development services, Alfa Cytology is committed to delivering high-quality scientific support. Our expert team, state-of-the-art facilities, and comprehensive solutions empower your HTLV-1 drug development projects for success. Contact us for more information or to arrange a consultation.